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Abstract
Objective To investigate if the widely publicized warnings in 2003 from
the US Food and Drug Administration about a possible increased risk
of suicidality with antidepressant use in young people were associated
with changes in antidepressant use, suicide attempts, and completed
suicides among young people.
DesignQuasi-experimental study assessing changes in outcomes after
the warnings, controlling for pre-existing trends.
Setting Automated healthcare claims data (2000-10) derived from the
virtual data warehouse of 11 health plans in the US Mental Health
Research Network.
Participants Study cohorts included adolescents (around 1.1 million),
young adults (around 1.4 million), and adults (around 5 million).
Main outcome measures Rates of antidepressant dispensings,
psychotropic drug poisonings (a validated proxy for suicide attempts),
and completed suicides.
Results Trends in antidepressant use and poisonings changed abruptly
after the warnings. In the second year after the warnings, relative
changes in antidepressant use were −31.0% (95% confidence interval
−33.0% to −29.0%) among adolescents, −24.3% (−25.4% to −23.2%)
among young adults, and −14.5% (−16.0% to −12.9%) among adults.
These reflected absolute reductions of 696, 1216, and 1621 dispensings
per 100 000 people among adolescents, young adults, and adults,
respectively. Simultaneously, there were significant, relative increases
in psychotropic drug poisonings in adolescents (21.7%, 95% confidence
interval 4.9% to 38.5%) and young adults (33.7%, 26.9% to 40.4%) but
not among adults (5.2%, −6.5% to 16.9%). These reflected absolute
increases of 2 and 4 poisonings per 100 000 people among adolescents
and young adults, respectively (approximately 77 additional poisonings
in our cohort of 2.5 million young people). Completed suicides did not
change for any age group.
Conclusions Safety warnings about antidepressants and widespread
media coverage decreased antidepressant use, and there were
simultaneous increases in suicide attempts among young people. It is
essential to monitor and reduce possible unintended consequences of
FDA warnings and media reporting.
Correspondence to: C Y Lu 133 Brookline Avenue, 6th Floor, Boston, MA 02215, USA christine_lu@harvardpilgrim.org
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Introduction
Conflicting evidence on the true effects of antidepressants on
suicide risk in young people has generated much controversy.1-7
Between 2003 and 2004 the US Food and Drug Administration
issued several health advisories warning that children and
adolescents taking antidepressants were at increased risk of
suicidality (suicidal ideation and behavior). In October 2004
the FDA required a boxed warning of this risk to be on the labels
of all antidepressant drugs. In May 2007 the FDA extended the
warnings to include young adults.
The basis for the decision on the boxed warning has been
contentious.8 9An FDA solicitedmeta-analysis showed a relative
risk for suicidal behavior or ideation of 1.95 (95% confidence
interval 1.28 to 2.98) for young people treated with
antidepressants compared with those given placebo.4 However,
the trials included in the meta-analysis were never designed to
estimate the risk of suicidality.4 9 Also, the majority of adverse
events reported in the meta-analysis involved suicidal ideation,
not suicide attempts or completed suicides.4 8 9 Despite this
inconclusive evidence, the FDA advisories and the boxed
warning received repeated and widespread media coverage in
major newspapers and television networks.10Many news stories
used anecdotes and emphasized the risk of antidepressant use
by children and adolescents.10 Thus, well intended safety
warnings became frightening alarms to clinicians, parents, and
young people. For example, oneNew York Times headline stated
“FDA links drugs to being suicidal,”11 and another in the
Washington Post reported “FDA confirms antidepressants raise
children’s suicide risk.”12
Suicide among young people is a devastating but preventable
tragedy. In the United States in 2007, suicide was the third
leading cause of death among people aged 15 to 24.13 Nearly
8% of high school students reported attempting suicide in 2011
and 2.4% made an attempt that required medical attention.14
There has been considerable concern that suicidal behavior is
a potential adverse outcome of prescription drug use, including
antidepressant and anticonvulsant agents.15
Treating depression in young people with antidepressants can
improvemood.16-18However, the relation between antidepressant
use and suicidal behavior is complex, and studies using different
methods yield apparently contradictory results. Pre-existing
suicidal ideation or behavior may be a precipitant for initiating
antidepressant treatment.7While treatment with antidepressants
may reduce that pre-existing risk of suicidal ideation, this finding
may not hold in young people.18 In adolescents and young adults,
initiation of antidepressant treatment may precipitate short term
increases in suicidal ideation and behavior.4 19 20 Given this
complexity, warnings about the safety of antidepressant drugs
could have unpredictable effects on drug use and suicidal
behavior.7
Previous studies of the FDA warnings have found substantial
reductions in antidepressant treatment in children and
adolescents after the warnings.21-24 The reduction even spilled
over to adults, who were never a target of the warnings.25 The
warnings were also associated with declines in depression
diagnoses in children and adults.21 22 25 Studies reported no
increase in use of treatment alternatives (for example,
psychotherapy, atypical antipsychotics) among young
people,21 22 24 and no increase in the monitoring of patients
despite an explicit call for this in the boxed warning.23 26
We investigated if the warnings and related media coverage
were associated with changes in antidepressant use and suicidal
behavior. Our study differs from previous studies in that it
provides empirical evidence about changes in suicide attempts
and completed suicides using nationwide, long term follow-up
after the FDA warnings (2005-10). Because depression is an
independent risk factor for suicidality, and appropriate treatment
with antidepressants is effective in reducing depressive
symptoms, we hypothesized that decreasing rates of overall
antidepressant treatment after the warnings would be associated
with a net increase in suicide attempts among young people.
Methods
Health plans and data source
This study included 11 geographically distributed US healthcare
organizations that provide care to a diverse population of 10
million people in 12 states. All organizations are members of
theMental Health ResearchNetwork (www.mhresearchnetwork.
org), a division of the larger HMO Research Network, an
established consortium of 19 research centers affiliated with
large not for profit integrated healthcare systems (www.
hmoresearchnetwork.org).27 Members are enrolled through
employer sponsored insurance, individual insurance plans, and
capitated Medicare and Medicaid programs. Members served
by these systems are generally representative of each system’s
geographic service area27 (see supplementary table A).
Data were obtained from the HMO Research Network Virtual
Data Warehouse.27-29 A common obstacle to multisite research
projects is the variation in automated data systems between
sites, making it challenging to generate datasets that can be
easily merged across sites. To overcome this, the virtual data
warehouse is a series of data standards and automated processes
that guide the generation of similarly constructed data tables at
each organization. In this federated data structure, protected
health information remains at each organization, but common
data definitions and formats facilitate sharing of deidentified
data for research. The virtual data warehouse includes
information on demographics, health plan enrollment, utilization
of inpatient and outpatient care, and outpatient pharmacy data.
At each site, source data are extracted from the health plan
administrative and claims databases and electronic medical
records. The virtual data warehouse also includes date (month,
year) and information on causes of death, derived from state
death registries and internal health plan data. There is generally
a lag time of 12-24 months for both reporting of deaths and
availability of data; therefore we analyzed data on deaths up to
and including 2008. To develop each site’s study dataset,
standardized programs were written at the lead study site and
distributed to participating sites. Each site executed the programs
on its virtual data warehouse tables and returned the resulting
dataset to the lead site, where site specific study datasets were
combined and analyzed. This study was approved by
institutional ethics committees at each participating site as well
as from state departments of public health when required for
the use of information from death certificates.
Study cohorts and outcome measures
Study cohorts included all adolescents (ages 10-17), young
adults (ages 18-29), and adults (ages 30-64). We used these
cut-offs because the prevalence of serious suicidal thoughts,
planning, and attempts is higher among young adults aged 18-29
than among adults aged 30 and older, based on national data
from the US Centers for Disease Control and Prevention.30
Adults were not targeted by the warnings and were included as
a “control” group. Because previous studies showed that rates
of depression diagnosis changed after the warnings21 22 25 and
that outpatient claims are often incomplete for mental health
conditions such as depression,31 32 to avoid introducing selection
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bias, we did not limit our cohorts to those with a coded diagnosis
of depression.
To assess changes in antidepressant use after the warnings, we
identified a rolling cohort of continuous enrollees.We calculated
the quarterly percentage of enrollees who were dispensed an
antidepressant. We included all antidepressant agents because
the warnings affected the entire therapeutic class.
To examine changes in suicide attempts after the warnings, we
used the same denominator population as defined previously.
While encounters for suicide attempts can be identified in
administrative databases using external cause of injury codes
(E-codes), they are known to be incompletely captured in
commercial plan databases.33 Our preliminary analysis found
that E-code completeness varied across study sites, treatment
settings, and years.34 Therefore, instead of deliberate self harm
E-codes, we used poisoning by psychotropic agents
(international classification of diseases, ninth revision, clinical
modification (ICD-9) code 969), a more reliable proxy for
population level suicide attempts.33 34 Poisoning by drugs or
toxic substances is the most commonmethod of suicide attempt
leading to hospital admission33 and emergency room
treatments.35 36 Non-fatal poisoning by psychotropic drugs
(predominantly tranquilizers) has a positive predictive value of
79.7% for suicide attempts (sensitivity was 38.3% and specificity
was 99.3%), outperforming other types of injuries or
poisonings.33We calculated the quarterly percentage of enrollees
admitted to hospital or treated in emergency rooms for poisoning
by a psychotropic drug. In a sensitivity analysis we also
calculated the quarterly percentage of enrollees admitted to
hospital or treated in emergency rooms for poisoning by any
drugs (including non-psychotropic agents such as narcotics and
analgesics; ICD-9 codes 960-979).
To examine changes in completed suicides after the warnings,
we identified a rolling denominator consisting of people who
had enrolled in the health plan for a given quarter or the month
immediately before that quarter. We did not require continuous
enrollment because health plan membership is terminated by
death. We identified deaths with suicide as a cause of death
(ICD-10 codes X60-X84, Y87.0)6 and calculated the quarterly
number of completed suicides per 100 000 people.
Study design and statistical analysis
We used an interrupted times series design,37which can provide
powerful evidence of causal effects because it controls for
secular trends in study outcomes. The approach measures
whether or not a policy (in this study the FDAwarnings) causes
abrupt changes in the level or the pre-existing trend (slope) of
study outcomes.37
Time series of population rates are divided into three segments:
the pre-warning period (first quarter of 2000 to third quarter of
2003), “phase-in” period (last quarter of 2003 to last quarter of
2004), and post-warning period (first quarter of 2005 to last
quarter of 2010). The first segment comprised rates of study
outcomes before the FDAwarnings. To deal with the possibility
of an anticipatory response to the warnings, we considered the
last quarter of 2003 to the last quarter of 2004 as a “phase-in”
period that spanned the entire period of FDA advisories, the
boxed warning, and intense media coverage, and excluded these
five data points from the regression models. Excluding these
observations also allowed for patients and clinicians to learn
about the evidence and consider changing their patterns of
antidepressant use. Thus, the approach evaluated the effects of
the warnings at “full strength.” The final segment comprised
rates of study outcomes after the warnings.
We used segmented regression models37 to estimate changes at
cohort level in our outcome measures from the pre-warnings
period to the post-warnings period. A segmented regression
model statistically estimates the differences in intercept and
slope coefficients between the pre-warning and post-warning
periods. We analyzed each age group separately. In statistical
models, we adjusted for baseline (control) trends and for
seasonal trends. The models included a binary indicator to
estimate the immediate level change in outcomes and a term to
estimate the trend change after the warnings. While segmented
regression models primarily have a linear specification,
polynomial and non-linear regression can be used if the data
exhibit non-linear patterns. We included a quadratic term for
the post-warnings trend in our models because of observed
non-linearity. For parsimony, we excluded non-significant
(P≥0.20) time series terms in a stepwise fashion; exclusion of
the non-significant terms did not change the coefficients on the
remaining terms.37 We controlled for all significant
autocorrelation terms in the models because observations over
time are correlated. In addition, we also provided absolute and
relative differences (with 95% confidence intervals)38 in the
second year after the warnings (that is, in the last quarter of
2006), which were estimated by comparing the overall changes
in outcome attributable to the warnings with counterfactual
estimates of what would have happened without the warnings.
We conducted all statistical analyses using SAS (version 9.3,
SAS Institute, Cary, NC).
Results
The study cohorts included approximately 1.1 million
adolescents, 1.4 million young adults, and 5 million adults per
quarter; the key characteristics were stable over time (table 1⇓).
Figures 1 to 3⇓⇓⇓ present the 2000-10 time series of
antidepressant dispensings and psychotropic drug poisonings
with segmented regression results by age group. Estimated
changes in levels and trends of time series from segmented
regression models are available in the supplementary file (table
B). For ease of interpretation, we also present absolute and
relative changes to represent the full effect of the widely
publicized warnings in the second year after the warnings.
Changes in dispensings of selective serotonin reuptake inhibitors
and serotonin-norepinephrine reuptake inhibitors are available
in the supplementary file (table C).
Effects of the warnings
Adolescents
After the warnings, there was an abrupt decline in the previously
upward trend of antidepressant use by adolescents (fig 1). We
estimated a relative reduction of 31.0% in antidepressant use in
the second year after the warnings (95% confidence interval
−33.0% to −29.0%; table 2⇓); the absolute change was −0.70
percentage points (95% confidence interval −0.76 to −0.63).
At the same time as the substantial reduction in antidepressant
use, we observed a sharp increase in psychotropic drug
poisonings (fig 1). We estimated a significant relative increase
of 21.7% in psychotropic drug poisonings in the second year
after the warnings (95% confidence interval 4.9 to 38.5); the
absolute change was 0.002 percentage points (0.0007 to 0.0033).
Increases in psychotropic drug poisonings were statistically
significant among males (table 2). Our sensitivity analysis also
detected a significant relative increase of 13.9% (10.0% to
17.8%) in poisonings by any drugs among adolescents in the
second year after the warnings.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g3596 doi: 10.1136/bmj.g3596 (Published 18 June 2014) Page 3 of 11
RESEARCH
Completed suicides were rare. Figure 1 presents three point
moving averages of quarterly suicide rates over time, adjusting
for seasonal trends. We did not observe changes in completed
suicides among adolescents; suicide rates ranged from 0.31 to
0.82 per 100 000 people per quarter before the warnings, and
from 0.28 to 0.68 per 100 000 people per quarter after the
warnings.
Young adults
After the warnings, there was an immediate reversal of the
upward trend of antidepressant use in young adults (fig 2). We
observed a relative reduction of 24.3% in antidepressant use in
the second year after the warnings (−25.4% to −23.2%; table
2); the absolute change was −1.22 percentage points (−1.29 to
−1.14). Simultaneously, there was a noticeable increase in
psychotropic drug poisonings (fig 2), with a relative increase
of 33.7% in the second year after the warnings (26.9% to 40.4%)
and an absolute change of 0.004 percentage points (0.0033 to
0.0047). Increases in psychotropic drug poisonings were
significant among both sexes (table 2). We observed consistent
increases in psychotropic drug poisonings in study sites located
in different regions across the country when we combined
adolescent and young adult groups (data not shown owing to
research ethics and privacy regulations; absolute changes ranged
from 0.001 to 0.019 percentage points). Our sensitivity analysis
did not detect changes in poisonings by any drugs after the
warnings among young adults.
Completed suicide rates appeared to be stable, ranging from
1.25 to 1.76 per 100 000 people per quarter before the warnings,
and from 1.33 to 1.85 per 100 000 people per quarter after the
warnings (fig 2). We did not observe discontinuities in
completed suicides whenwe combined the data from adolescents
and young adults.
Adults
After the warnings, antidepressant use decreased suddenly
among adults (fig 3). In the second year after the warnings there
was a relative reduction of 14.5% in antidepressant use (−16.0%
to −12.9%; table 2); the absolute change was −1.62 percentage
points (−1.83 to −1.41). There was a statistically insignificant
increase in the trend of psychotropic drug poisonings after the
warnings (fig 3); we estimated a relative increase of 5.2% in
the second year after the warnings (−6.5 to 16.9) and an absolute
increase of 0.0005 percentage points (−0.0006 to 0.0016). Our
sensitivity analysis did not find changes in poisonings by any
drugs after the warnings among adults. There was no change in
completed suicides (fig 3), ranging from 1.76 to 2.06 per 100
000 people per quarter before the warnings, and from 1.86 to
2.27 per 100 000 people per quarter after the warnings.
Discussion
Whether or not a link exists between the use of antidepressant
drugs and the emergence of suicidal ideation and behavior in a
subset of young people, widely publicized warnings for
antidepressants and suicidality could have intended and
unintended effects. As hypothesized, we found substantial
reductions in antidepressant use, and simultaneous, small
increases in psychotropic drug poisonings, a validated measure
of suicide attempts, among adolescents and young adults after
the FDA warnings targeting youth and widespread media
coverage. These results were consistent across our
geographically diverse study sites.We did not observe increases
in psychotropic drug poisonings among adults, who had smaller
reductions in antidepressant use.
Our finding of reduced antidepressant use in young people is
consistent with previous studies.21-25Although the FDA extended
the warnings to include young adults in May 2007, this single
additional communication did not add to the effects of the
2003-04 widely publicized warnings; we did not observe further
abrupt changes in antidepressant use among young adults or
other age groups. After 2008, the downward trend in
antidepressant use among adolescents reversed somewhat;
however, utilization remained below 2004 levels. This change
may mean that the initial effects of the warnings tapered off or
that theMay 2007modification to the FDAmessages increased
antidepressant use. In the modified message, clinicians and the
public were urged to consider the risk of antidepressants
alongside the risk of not treating mood disorders.39
Our study provides the first evidence that suicide attempts
increased rather than decreased after the warnings. Relative
increases in non-fatal psychotropic drug poisonings were 21.7%
among adolescents and 33.7% among young adults in the second
year after the warnings. These reflected absolute increases of
77 poisonings in our cohort of 2.5 million young people (22
and 55 additional poisonings among adolescents and young
adults, respectively; 2 and 4 additional poisonings per 100 000
people). The estimated excess risk of suicide attempt is an
underestimate because it is based only on the second year of
follow-up and does not include other means of suicide attempts.
Since the increase in suicide attempts by poisoning was
simultaneous with the significant reductions in antidepressant
use, it might be one consequence of under-treatment of mood
disorders. This explanation is bolstered by other studies that
have found no compensating increases in the use of treatment
alternatives among young people.21 22 24
Our study was the first to examine the effects of the warnings
on completed suicides over a long period. In contrast with the
increases in suicide attempts, even with large sample sizes we
observed no changes in suicides after the warnings. Completed
suicides are rare; only one tenth as common as suicide attempts.
Nevertheless, our data are consistent with the Centers for
Disease Control and Prevention report that showed gradual
increases in completed suicides between 1999 and 2010, without
sudden discontinuities around the time of the FDA warnings
and media reports, among people aged 10-34 years.40
Policy implications
It is possible that the warnings and extensive media attention
led to unexpected and unintended population level reductions
in treatment for depression and subsequent increases in suicide
attempts among young people. FDA advisories and boxed
warnings can be crude and inadequate ways to communicate
new and sometimes frightening scientific information to the
public. Also, the information may be oversimplified and
distorted when communicated in the media.10 However, we
know that the media can influence drug use behavior in positive
ways. For example, high profile news reports substantially
reduced aspirin use in children and helped eradicate Reye’s
syndrome.41 Greater efforts are needed to improve risk
communications to the public and to health professionals. Active
surveillance should be considered to allow timely detection and
prompt actions to reduce unintended consequences of strong
warnings.
Strengths and limitations of this study
We used an interrupted time series design, which is robust
against most threats to internal validity. This study design
controls for secular trends in study outcomes (for example, the
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apparent growing epidemic in use of prescription psychotropic
drugs outside FDA approved indications) and thereby can
attribute abrupt changes to the widely publicized warnings.42
Several limitations of this study merit discussion. Firstly, as in
other studies using administrative data, we were only able to
measure psychotropic drug poisonings that were related to
receipt of medical attention, thereby underestimating the true
impact of the warnings on suicidality because only about a third
of suicide attempts are medically treated.14 Secondly, we elected
not to use deliberate self harm E-codes because they are
incompletely coded across sites in the Mental Health Research
Network and in commercial plan databases generally.34 Thirdly,
we elected not to use a validated algorithm33 based on a
combination of diagnoses of injury and psychiatric conditions,
including depression, to avoid introducing ascertainment bias
because previous research found that the rates of depression
diagnosis declined after the warnings.21 22 25 Instead, we used
psychotropic drug poisonings to estimate changes in suicide
attempts after the warnings. While the positive predictive value
of psychotropic drug poisonings is lower than the
abovementioned algorithm (79.7% v 87.8%), it outperforms
other injury and poisoning types and has high specificity.33Given
that each method only accounts for a small subset of suicide
attempts, which are rare, we would not be able to detect any
change in population level rates of suicide attempts by other
means even with our large sample of 7.5 million. Because
psychotropic drug poisonings account for about 38% of suicide
attempts,33 36 our results underestimate increases in suicide
attempts after the warnings. Further, our sample largely included
insured populations (commercial plans and public insurers); the
findings may not reflect behavior among uninsured patients.
Our data sources did not have reliable information on
socioeconomic status and race or ethnicity for the early 2000s,
thus we did not stratify our analyses by these factors. Finally,
our interrupted time series of population rates cannot be used
to make inferences about patient level outcomes.
Notwithstanding these limitations, given our study’s
quasi-experimental design with long term follow-up, we provide
rigorous evidence that the FDA warnings and media coverage
led to substantial reductions in antidepressant use, which were
associated with small increases in suicide attempts by poisonings
among young people.
Conclusions
Undertreated mood disorders can have severe negative
consequences. Thus, it is disturbing that after the health
advisories, warnings, and media reports about the relation
between antidepressant use and suicidality in young people, we
found substantial reductions in antidepressant treatment and
simultaneous, small but meaningful increases in suicide
attempts. It is essential to monitor and reduce possible
unintended effects of FDA warnings and media reporting.
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Tables
Table 1| Cohort characteristics. Values are percentages unless stated otherwise
Post-warningsPhase-inPre-warnings
Characteristics 2010, last quarter2008, last quarter2006, last quarter2004, 2nd quarter2002, last quarter2001, last quarter
7 618 5127 473 3857 399 5867 167 3977 303 4927 179 024Total No
Age (years):
14.114.314.715.715.014.910-17
18.918.918.518.219.119.418-29
67.066.866.766.166.065.730-64
Aged 10-17:
1 070 5221 069 1521 090 4311 124 1421 091 6511 071 473Total No
49.049.149.049.049.049.0Female
43.0†42.642.843.142.642.8High SES*
Aged 18-29:
1 442 3811 410 4351 370 7641 306 0381 391 1901 388 960Total No
52.952.652.552.952.852.8Female
47.5†46.646.346.045.145.0High SES*
Aged 30-64:
5 105 6094 993 7984 938 3914 737 2174 820 6514 718 591Total No
52.752.452.252.252.052.0Female
50.1†49.549.749.849.249.3High SES*
Warnings refer to the widely publicized Food and Drug Administration’s advisories and a boxed warning about antidepressant use and the risk of suicidality among
young people.
*Based on census data. High SES (socioeconomic status)=members residing in neighborhoods where >25% of adults were educated at college.
†Calculated based on last quarter of 2009.
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Table 2| Absolute and relative changes in outcomes in second year after warnings compared with expected rates derived from baseline
trend
Suicide attempts*All antidepressants
Populations
Absolute change
per 100 000 peopleRelative change (%)Absolute change
Absolute change per
100 000 peopleRelative change (%)Absolute change
Overall:
2 (0.73 to 3.30)21.70 (4.94 to 38.45)0.0020 (0.0007 to
0.0033)
−696 (−761 to −632)−30.97 (−33.0 to
−28.96)
−0.70 (−0.76 to
−0.63)
Children and
adolescents
4 (3.33 to 4.73)33.68 (26.93 to
40.43)
0.0040 (0.0033 to
0.0047)
−1216 (−1291 to
−1142)
−24.29 (−25.42 to
−23.16)
−1.22 (−1.29 to
−1.14)
Young adults
0.52 (−0.60 to 1.64)5.19 (−6.51 to 16.89)0.0005 (−0.0006 to
0.0016)
−1621 (−1827 to
−1414)
−14.46 (−16.04 to
−12.88)
−1.62 (−1.83 to
−1.41)
Adults
Females:
0.26 (−0.50 to 1.01)1.74 (−3.41 to 6.88)0.0003 (−0.0005 to
0.0010)
−892 (−959 to −824)−34.63 (−36.39 to
−32.88)
−0.89 (−0.96 to
−0.82)
Children and
adolescents
5.05 (4.24 to 5.86)35.94 (29.21 to
42.66)
0.0051 (0.0042 to
0.0059)
−1749 (−1846 to
−1652)
−25.37 (−26.43 to
−24.31)
−1.75 (−1.84 to
−1.65)
Young adults
0.99 (−0.77 to 2.74)7.65 (−6.93 to 22.23)0.0010 (−0.0008 to
0.0027)
−2352 (−2636 to
−2068)
−15.27 (−16.84 to
−13.70)
−2.35 (−2.64 to
−2.07)
Adults
Males:
3.90 (2.47 to 5.33)104.30 (26.65 to
181.91)
0.0039 (0.0025 to
0.0053)
−507 (−575 to −439)−26.24 (−28.88 to
−23.59)
−0.51 (−0.57 to
−0.44)
Children and
adolescents
3.18 (2.39 to 3.96)33.84 (24.08 to
43.61)
0.0032 (0.0024 to
0.0040)
−597 (−670 to −524)−20.65 (−22.67 to
−18.63)
−0.60 (−0.67 to
−0.52)
Young adults
−0.47 (−1.44 to 0.50)−6.07 (−17.93 to
5.78)
−0.0005 (−0.0014 to
0.0005)
−835 (−977 to −693)−12.55 (−14.44 to
−10.68)
−0.84 (−0.98 to
−0.69)
Adults
Observation period: first quarter of 2000 to last quarter of 2010, with data points from phase-in period (last quarter of 2003 to last quarter of 2004) excluded from
regression models.
*Identified by poisonings using psychotropic agents (ICD-9 code 969).
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Figures
Fig 1 Rates of antidepressant use, psychotropic drug poisonings, and completed suicides per quarter before and after the
warnings among adolescents enrolled in 11 health plans in nationwide Mental Health Research Network
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Fig 2 Rates of antidepressant use, psychotropic drug poisonings, and completed suicides per quarter before and after the
warnings among young adults enrolled in 11 health plans in nationwide Mental Health Research Network
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Fig 3 Rates of antidepressant use, psychotropic drug poisonings, and completed suicides per quarter before and after the
warnings among adults enrolled in 11 health plans in nationwide Mental Health Research Network
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